Boussard & Gavaudan Investment Management LLP Takes Position in Insulet Co. (NASDAQ:PODD)

Boussard & Gavaudan Investment Management LLP purchased a new position in Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 7,732 shares of the medical instruments supplier’s stock, valued at approximately $2,036,000.

A number of other hedge funds also recently bought and sold shares of PODD. Baillie Gifford & Co. boosted its holdings in shares of Insulet by 3.5% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after purchasing an additional 79,982 shares during the period. Geode Capital Management LLC boosted its stake in Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after buying an additional 22,850 shares during the period. Norges Bank bought a new position in Insulet during the fourth quarter valued at $248,806,000. Artisan Partners Limited Partnership increased its position in Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock valued at $201,073,000 after acquiring an additional 149,524 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Insulet by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier’s stock worth $168,902,000 after acquiring an additional 10,694 shares during the last quarter.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Insulet Trading Down 1.7 %

NASDAQ:PODD opened at $260.27 on Friday. The firm has a 50 day moving average of $272.03 and a 200 day moving average of $258.25. The stock has a market capitalization of $18.28 billion, a price-to-earnings ratio of 44.95, a PEG ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, sell-side analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the topic of several analyst reports. Citigroup upped their price target on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a report on Friday, February 21st. Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Piper Sandler increased their target price on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Stifel Nicolaus boosted their target price on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.